Stock comparison
Cintas
Strata Critical Medical
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CTAS
Cintas
Market cap
$69.19B
Sector
Industrials
SRTA
Strata Critical Medical
Market cap
$530.41M
Sector
Industrials
Overall winner
Cintas CTAS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CTAS | SRTA | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 31F | CTAS |
| Benjamin Graham | 84A | 33F | CTAS |
| Philip Fisher | 72B | 45D | CTAS |
| Peter Lynch | 68B | 74C | SRTA |
| Joel Greenblatt | 69B | 27F | CTAS |
| Charlie Munger | 80A | 40D | CTAS |
| Terry Smith | 75B | 37D | CTAS |
Side-by-side metrics
| Metric | CTAS | SRTA |
|---|---|---|
| Market cap | $69.19B | $530.41M |
| P/E (TTM) | 34.9x | 8.8x |
| EV/EBIT | 29.7x | - |
| ROIC (TTM) | 23.17% | -4.92% |
| Gross margin | 50.36% | 20.52% |
| Net margin | 17.57% | 19.97% |
| Revenue CAGR 5y | 9.79% | 40.55% |
| EPS CAGR 5y | 14.24% | - |
| Debt / Equity | 0.6x | 0.0x |
| Dividend yield | 1.07% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CTAS leads on
- ROIC (TTM)23.17%vs -4.92%+121%
- Dividend yield1.07%vs 0.0%+100%
- Market cap$69.19Bvs $530.41M+99%
- Gross margin50.36%vs 20.52%+59%
SRTA leads on
- EV/EBIT-vs 29.7x+173%
- Debt / Equity0.0xvs 0.6x+97%
- Revenue CAGR 5y40.55%vs 9.79%+76%
- P/E (TTM)8.8xvs 34.9x+75%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.